SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.139+0.9%Nov 7 9:30 AM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: TripleE31/27/2025 9:15:57 AM
2 Recommendations

Recommended By
dorightbythem
erippetoe

  Read Replies (2) of 1230
 
ImmunityBio announces european medicines agency acceptance of marketing authorization application for ANKTIVA for the Treatment of Patients with BCG-unresponsive non-muscle invasive bladder cancer carcinoma

Application covers 30 countries in the European Union. Submission is based on the ongoing QUILT 3.032 study in which 100 patients with Bacillus Calmette-Gurin (BCG)-unresponsive non-muscle invasive bladder cancer with carcinoma in situ ( NMIBC CIS) have been treated with ANKTIVA (nogapendekin alfa inbakicept-pmln) in combination with BCG, achieving a 71% (71/100) complete response rate. In these responders, the range of duration is 54 months and ongoing, exceeding all duration of response in approved products in this indication.

Hope to see quick approval!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News